Access to CAR-T therapy in Latin America: Barriers, gaps, and pathways forward
Point-of-care manufacturing and allogeneic approaches could reduce CAR-T therapy costs by 90% and expand access across Latin America.
Weill Cornell researchers review the landscape of CAR-T access barriers in Latin America, highlighting cost, manufacturing complexity, infrastructure gaps, and under-representation in clinical trials as primary obstacles. Emerging solutions including decentralized point-of-care manufacturing with >90% cost reduction, off-the-shelf allogeneic products, and mRNA-based approaches offer concrete pathways toward CAR-T equity in the region.
What the study was
- Study design
- Narrative review
- Population
- Patients with hematologic malignancies (diffuse large B-cell lymphoma, B-cell leukemias, multiple myeloma) in Latin American and LMIC settings
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Seminars in Immunology
Why it surfaced
Health equity review addressing CAR-T access in LMIC; >90% cost reduction data in pilot programs is the key quantitative signal; relevant to global access agenda for hematologic malignancy treatment
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.